All articles by Joshua Silverwood

Joshua Silverwood

Investors inject $60m in AI patient management start up Fabric

The funding comes alongside the company’s acquisition of conversational AI firm Gyant.

FDA warns of fraudulent data coming from third party labs

The US Food and Drug Administration has warned that some third-party labs, many based out of India and China, are producing false or duplicated data.

Reprieve lands $42m to advance heart failure trials

The funding is being used to accelerate the company’s FASTR Trial, which is examining the company’s system for the treatment of acute decompensated heart failure.

X-trodes swings FDA 510(k) clearance for at-home electrophysiological system

The patient monitoring device was designed as an alternative to in-clinic tests designed to track a patient’s biopotential signals from brain activity to eye movement.

New UK medical device industry body Team-AB officially launches

The new body has launched with backing from 11 medical device certification bodies.

Study finds 90% of UK public say diagnostic test access is not sufficient

The study commissioned by the The Patients Association found that patients seeking diagnostic tests are burdened with long waits and the majority would rather test at home.

Freenome swings $254m investment

The funding comes as the company works to advance three clinical trials examining early cancer assessments across a few indications.

Enable Injections expands manufacturing with 90,000ft² facility

The expansion follows market clearance of Enable’s EnFuse wearable injector system and a renovation of the company’s headquarters.

UK Government invests £10m to rush devices to market

The £10m ($12.5m) funding initiative is aimed at boosting the NHS by accelerating the development of medical devices across multiple applications ranging from identifying Alzheimer’s to predicting chronic obstructive pulmonary disease.

Testing, testing: the advancing diagnostics for sexually transmitted infections

Amid a worldwide spike in sexually transmitted infections, medtech companies are racing to stem the tide and develop diagnostics that stay one step ahead of people’s habits.